Endometrial Carcinoma: Specific Targeted Pathways.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Advances in Experimental Medicine and Biology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-319-43139-0_6PMID 27910068
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28.

  2015cited by this paper
• Raf‐interactome in tuning the complexity and diversity of Raf function

  2015cited by this paper
• Entry into mitosis: a solution to the decades-long enigma of MPF

  2015cited by this paper
• Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.

  2015cited by this paper
• Cell-Cycle Protein Expression in a Population-Based Study of Ovarian and Endometrial Cancers

  2015cited by this paper
• Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: endometrial cancer as a model.

  2015cited by this paper
• Prognostic value of cyclin B in endometrial endometrioid adenocarcinoma

  2015cited by this paper
• Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer

  2015cited by this paper
• The history and future of targeting cyclin-dependent kinases in cancer therapy

  2015cited by this paper
• Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.

  2014cited by this paper
• Cyclin-dependent kinases

  2014cited by this paper
• Highlights of the Latest Advances in Research on CDK Inhibitors

  2014cited by this paper
• Hypoxia-Controlled EphA3 Marks a Human Endometrium-Derived Multipotent Mesenchymal Stromal Cell that Supports Vascular Growth

  2014cited by this paper
• MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression

  2014cited by this paper
• RNF43 is frequently mutated in colorectal and endometrial cancers

  2014cited by this paper
• Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma.

  2014cited by this paper
• Inhibitory effect of 2-(piperidinoethoxyphenyl)-3-(4-hydroxyphenyl)-2H-benzo(b)pyran (K-1) on human primary endometrial hyperplasial cells mediated via combined suppression of Wnt/β-catenin signaling and PI3K/Akt survival pathway

  2014cited by this paper
• Molecular Alterations of PI3K/Akt/mTOR Pathway: A Therapeutic Target in Endometrial Cancer

  2014cited by this paper
• Uterine epithelial cell proliferation and endometrial hyperplasia: evidence from a mouse model.

  2014cited by this paper
• A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.

  2014cited by this paper
• High expression of cyclin A is associated with poor prognosis in endometrial endometrioid adenocarcinoma

  2014cited by this paper
• Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor

  2014cited by this paper
• A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

  2014cited by this paper
• MEK1/2 inhibitors in the treatment of gynecologic malignancies.

  2014cited by this paper
• Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

  2014cited by this paper
• Targeting RAS–ERK signalling in cancer: promises and challenges

  2014cited by this paper
• “RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway

  2014cited by this paper
• Synergistic in vitro anti-tumor effect of letrozole and everolimus on human endometrial carcinoma Ishikawa cells.

  2014cited by this paper
• A novel wnt regulatory axis in endometrioid endometrial cancer.

  2014cited by this paper
• A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.

  2014cited by this paper
• Dragging ras back in the ring.

  2014cited by this paper
• Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.

  2014cited by this paper
• Abstract 205: Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells

  2014cited by this paper
• Safely targeting cancer stem cells via selective catenin coactivator antagonism

  2014cited by this paper
• Signalling pathways in endometrial cancer

  2014cited by this paper
• Over-Expression of Platelet-Derived Growth Factor-D Promotes Tumor Growth and Invasion in Endometrial Cancer

  2014cited by this paper
• JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations

  2013cited by this paper
• Molecular pathology of endometrial carcinoma

  2013cited by this paper
• HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.

  2013cited by this paper
• A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

  2013cited by this paper
• IGF1R-directed targeted therapy enhances the cytotoxic effect of chemotherapy in endometrial cancer.

  2013cited by this paper
• Mechanisms of acquired resistance to ERK1/2 pathway inhibitors

  2013cited by this paper
• Long-term estradiol exposure is a direct mitogen for insulin/EGF-primed endometrial cells and drives PTEN loss-induced hyperplasic growth.

  2013cited by this paper
• PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines

  2013cited by this paper
• Overexpression of the Insulin Receptor Isoform A Promotes Endometrial Carcinoma Cell Growth

  2013cited by this paper
• Effects of insulin, insulin-like growth factor-I and -II on proliferation and intracellular signaling in endometrial carcinoma cells with different expression levels of insulin receptor isoform A.

  2013cited by this paper
• An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias

  2013cited by this paper
• Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974

  2013cited by this paper
• Oncogene alterations in endometrial carcinosarcomas.

  2013cited by this paper
• MUC20 overexpression predicts poor prognosis and enhances EGF-induced malignant phenotypes via activation of the EGFR-STAT3 pathway in endometrial cancer.

  2013cited by this paper
• Integrated genomic characterization of endometrial carcinoma

  2013cited by this paper
• Utilization of genomic signatures to identify high‐efficacy candidate drugs for chemorefractory endometrial cancers

  2013cited by this paper
• Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

  2013cited by this paper
• AKT inhibition mitigates GRP78 (glucose‐regulated protein) expression and contribution to chemoresistance in endometrial cancers

  2013cited by this paper
• Estradiol and Tamoxifen Induce Cell Migration through GPR30 and Activation of Focal Adhesion Kinase (FAK) in Endometrial Cancers with Low or without Nuclear Estrogen Receptor α (ERα)

  2013cited by this paper
• Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial

  2013cited by this paper
• GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia

  2013cited by this paper
• Relationship between PTEN, DNA Mismatch Repair, and Tumor Histotype in Endometrial Carcinoma: Retained Positive Expression of PTEN Preferentially Identifies Sporadic Non-Endometrioid Carcinomas

  2013cited by this paper
• Cyclin D1 localizes in the cytoplasm of keratinocytes during skin differentiation and regulates cell–matrix adhesion

  2013cited by this paper
• Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma.

  2013cited by this paper
• Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models

  2013cited by this paper
• A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma

  2013cited by this paper
• Regulation of small GTPases by GEFs, GAPs, and GDIs.

  2013cited by this paper
• A Wheat WRKY Transcription Factor TaWRKY10 Confers Tolerance to Multiple Abiotic Stresses in Transgenic Tobacco

  2013cited by this paper
• XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway

  2013cited by this paper
• In Vitro Effects of a Small-Molecule Antagonist of the Tcf/ß-Catenin Complex on Endometrial and Endometriotic Cells of Patients with Endometriosis

  2013cited by this paper
• Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

  2013cited by this paper
• Current status of molecular-targeted drugs for endometrial cancer (Review)

  2013cited by this paper
• Epidermal growth factor receptor signaling pathway involved in progestin‐resistance of human endometrial carcinoma: In a mouse model

  2012cited by this paper
• Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

  2012cited by this paper
• Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.

  2012cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin

  2012cited by this paper
• Cisplatin increases B‐cell‐lymphoma‐2 expression via activation of protein kinase C and Akt2 in endometrial cancer cells

  2012cited by this paper
• Inhibition of Tankyrases Induces Axin Stabilization and Blocks Wnt Signalling in Breast Cancer Cells

  2012cited by this paper
• FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features

  2012cited by this paper
• A comprehensive survey of Ras mutations in cancer.

  2012cited by this paper
• Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.

  2012cited by this paper
• MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2

  2012cited by this paper
• TGF‐β signaling in development and disease

  2012cited by this paper
• Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer

  2012cited by this paper
• MEK1/2 dual-specificity protein kinases: structure and regulation.

  2012cited by this paper
• Tyrosine Kinase Receptor Status in Endometrial Stromal Sarcoma: An Immunohistochemical and Genetic-Molecular Analysis

  2012cited by this paper
• The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer

  2012cited by this paper
• Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.

  2012cited by this paper
• ERK1/2 MAP kinases: structure, function, and regulation.

  2012cited by this paper
• Down-regulation of Sox7 is associated with aberrant activation of Wnt/β-catenin signaling in endometrial cancer

  2012cited by this paper
• Role of canonical Wnt signaling in endometrial carcinogenesis

  2012cited by this paper
• Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy

  2012cited by this paper
• Wnt/β-catenin signaling and disease.

  2012cited by this paper
• Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer.

  2012cited by this paper
• The insulin and insulin-like growth factor receptor family in neoplasia: an update

  2012cited by this paper
• Mechanisms of FGFR-mediated carcinogenesis.

  2012cited by this paper
• Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells

  2012cited by this paper
• Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

  2012cited by this paper
• A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.

  2012cited by this paper
• Systematic identification of genomic markers of drug sensitivity in cancer cells

  2012cited by this paper
• Mitogenic and anti-apoptotic effects of insulin in endometrial cancer are phosphatidylinositol 3-kinase/Akt dependent.

  2012cited by this paper
• Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.

  2012cited by this paper
• Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas

  2012cited by this paper

• EFFECT OF DOXORUBICIN AND PACLITAXEL ON THE SELECTIVE ONCOGENES EXPRESSION LEVEL OF HEPATOCELLULAR CARCINOMA RAS/RAF/MEK/ERK PATHWAY IN HUH-7 CELL LINE

  2024cites this paper
• Nanocarrier-based targeting of metabolic pathways for endometrial cancer: Status and future perspectives.

  2023cites this paper
• Evaluation of genes and molecular pathway related pathogenesis of endometriosis: A bioinformatics approach

  2023cites this paper
• Exploring the role of non-coding RNA mediated regulation of signaling pathways in endometrial cancer

  2023cites this paper
• LncRNA RBAT1 reduces chemosensitivity of cancer cells to carboplatin/paclitaxel by sponging miR‑27b in endometrial carcinoma

  2023cites this paper
• Construction of a prognostic model of luteolin for endometrial carcinoma.

  2023cites this paper
• A mechanism study of DUSP1 in inhibiting malignant progression of endometrial carcinoma by regulating ERK/AP-1 axis and dephosphorylation of EPHA2

  2023cites this paper
• Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression

  2022cites this paper
• Generation and Integrated Analysis of Advanced Patient‐Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial Cancer

  2022cites this paper
• Ion Channels in Endometrial Cancer

  2022cites this paper
• Mechanism investigation and experiment validation of capsaicin on uterine corpus endometrial carcinoma

  2022cites this paper
• A functional polymorphism in the poly(ADP-ribose) polymerase-1 gene increases the risk of endometrial carcinoma

  2022cites this paper
• FBXO17 Inhibits the Wnt/β-Catenin Pathway and Proliferation of Ishikawa Cells

  2022cites this paper
• FOXA2 suppresses endometrial carcinogenesis and epithelial-mesenchymal transition by regulating enhancer activity

  2022cites this paper
• The Role of CTNNB1 in Endometrial Cancer

  2022cites this paper
• The Role of mTOR and eIF Signaling in Benign Endometrial Diseases

  2022cites this paper
• Neutropenic enterocolitis-induced sepsis and disseminated intravascular coagulation after chemotherapy: a case report

  2021cites this paper
• Development of Potential Prognostic Biomarkers Based on DNA Methylation-Driven Genes for Patients with Endometrial Cancer

  2021cites this paper
• Resistance to chemotherapy among ethnic and racial groups: Health disparities perspective in gynecologic cancers

  2021cites this paper
• Canonical TGFβ Signaling and Its Contribution to Endometrial Cancer Development and Progression—Underestimated Target of Anticancer Strategies

  2021cites this paper
• Mechanism of Tetrandrine Against Endometrial Cancer Based on Network Pharmacology

  2021cites this paper
• Mycoplasma and Chlamydia Infection Can Increase Risk of Endometrial Cancer by Pro-inflammatory Cytokine Enlargement

  2021cites this paper
• The MCM3AP-AS1/miR-126/VEGF axis regulates cancer cell invasion and migration in endometrioid carcinoma

  2021cites this paper
• BarH-like homeobox 1 induces the progression of cell malignant phenotype in endometrial carcinoma through the regulation of ERK/MEK signaling pathway.

  2021cites this paper
• Genomics and splicing events of type II endometrial cancers in the black population: racial disparity, socioeconomic and geographical differences.

  2020cites this paper
• Hsa_circ_0001649 restrains gastric carcinoma growth and metastasis by downregulation of miR‐20a

  2020cites this paper
• Autophagy in the physiological endometrium and cancer

  2020cites this paper
• Key factors mediated by PI3K signaling pathway and related genes in endometrial carcinoma

  2020cites this paper
• Circ_0109046 promotes the malignancy of endometrial carcinoma cells through the microRNA‐105/SOX9/Wnt/β‐catenin axis

  2020cites this paper
• Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition

  2019cites this paper
• PI3K Pathway Effectors pAKT and FOXO1 as Novel Markers of Endometrioid Intraepithelial Neoplasia

  2019cites this paper
• Understanding Obesity as a Risk Factor for Uterine Tumors Using Drosophila.

  2019cites this paper
• Identification of key candidate genes and pathways in endometrial cancer: Evidence from bioinformatics analysis

  2019cites this paper
• Endometrial Cancer: From Biological to Clinical Approaches

  2019cites this paper
• YAP promotes the malignancy of endometrial cancer cells via regulation of IL-6 and IL-11

  2019cites this paper
• PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer

  2019cites this paper
• Association of TNFAIP8 gene polymorphisms with endometrial cancer in northern Chinese women

  2019cites this paper
• Epithelial to Mesenchymal Transition and Cell Biology of Molecular Regulation in Endometrial Carcinogenesis

  2019cites this paper
• Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.

  2019cites this paper
• Exploring lncRNA-Mediated Regulatory Networks in Endometrial Cancer Cells and the Tumor Microenvironment: Advances and Challenges

  2019influential citation
• Tumor-suppressive signaling in the uterus

  2019cites this paper
• Genomic Comparison of Endometrioid Endometrial Carcinoma and Its Precancerous Lesions in Chinese Patients by High-Depth Next Generation Sequencing

  2019cites this paper
• Dysregulation of Krüppel-like factor 12 in the development of endometrial cancer.

  2019cites this paper
• LRIG2 is a growth suppressor of Hec-1A and Ishikawa endometrial adenocarcinoma cells by regulating PI3K/AKT- and EGFR-mediated apoptosis and cell-cycle

  2018cites this paper
• 5-hydroxy-4′-nitro-7-propionyloxy-genistein inhibited invasion and metastasis via inactivating wnt/β-catenin signal pathway in human endometrial carcinoma JEC cells

  2018cites this paper
• BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

  2018cites this paper
• Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late

  2018cites this paper
• An update of Wnt signalling in endometrial cancer and its potential as a therapeutic target.

  2018cites this paper
• 5-Hydroxy-4′-Nitro-7-Propionyloxy-Genistein Inhibited Invasion and Metastasis via Inactivating Wnt/β-Catenin Signal Pathway in Human Endometrial Carcinoma Ji Endometrial Cells

  2018cites this paper
• HOXB9 promotes endometrial cancer progression by targeting E2F3

  2018cites this paper
• New therapies for advanced, recurrent, and metastatic endometrial cancers

  2017cites this paper
• Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients

  2017cites this paper
• Conditional abrogation of transforming growth factor‐β receptor 1 in PTEN‐inactivated endometrium promotes endometrial cancer progression in mice

  2017cites this paper